Blue Earth Diagnostics Completes Patient Accrual in Phase 3

- Clinical utility of 18F-fluciclovine being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization

Related Keywords

Italy , Milan , Lombardia , Ohio , United States , United Kingdom , Cleveland , Kostenloser Wertpapierhandel , Samuelt Chao , Davide Gauden , Eugenej Teoh , Clare Gidley , Mike Beyer , Priscilla Harlan , Emory University , Drug Administration , Emory University Department Of Radiology , Sam Brown Inc , Bracco Group , Nuclear Medicine , Corporate Communications , Imaging Sciences , Department Of Radiation Oncology , Ge Healthcare , Earth Diagnostics , Blue Earth Diagnostics , Chief Executive , Radiation Oncology , Cleveland Clinic , Cleveland Clinic Lerner College , Case Western Reserve University , Coordinating Investigator , Response Assessment , Chief Medical Officer , Blue Earth , Brain Metastases , Diagnostic Performance , Detecting Recurrent Brain , Negative Percent Agreement , Positive Percent Agreement , Positive Predictive Value , Negative Predictive Value , Recurrent Brain Metastases , Earth Diagnostic , Bracco Imaging , Interventional Radiology , Cardiac Catheterization , Magnetic Resonance Imaging , Contrast Enhanced Ultrasound , Blue Earth Therapeutics , Director Marketing , Blue , Earth , Iagnostics , Ompletes , Patient , Accrual , Hase , Revelate , Linical , Trial , Fluciclovine , Maging , Detection , Recurrent , Rain , Metastases ,